Search

everythinglearnresearchcommunity

for

Search:↓

Male and female skin differ in many ways, which could lead to gender-specific skin treatments.

Male and female bodies respond differently to stress, influenced by hormones and development stages, with implications for stress-related diseases.

Estrogens can improve skin aging but carry risks; more research is needed on safer treatments.

Menopause can lead to skin and hair problems due to hormonal changes, but hormone replacement therapy might help slow these effects.

Male and female skin differ due to hormones, affecting conditions like hair loss, acne, and skin cancer, and suggesting a need for gender-specific treatments.

Estrogen therapy can reduce skin aging but has cancer risks.

Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.

Estrogen replacement can improve skin health in menopausal women but doesn't reverse sun damage or prevent hair loss.

Estrogen loss during menopause worsens skin health, but hormone replacement therapy may improve it, though more research is needed.

The document concludes that blocking the internal pathways that create androgens might help treat cancers that depend on sex hormones.

Hair follicles produce and respond to melatonin, affecting hair growth and sensitivity to estrogen.

Hormones like estrogen, testosterone, progesterone, and prolactin play complex roles in female sexual function, with testosterone potentially improving sexual desire, arousal, and satisfaction. However, more research is needed to establish safe and effective hormone treatments for female sexual dysfunction.

Hormones and metabolism play a complex role in prostate enlargement, and more research is needed to improve diagnosis and treatment.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Menopause reduces skin collagen and elasticity, and while estrogen therapy can help, its risks require careful consideration.

Some hair loss can be treated, especially in women due to nutrition, but some types remain untreatable.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Sex steroids influence skin appendage function and neoplasm development, with changes in AR and ERalpha in certain gland neoplasms.

Frontal fibrosing alopecia mainly affects postmenopausal women and may be linked to thyroid hormones.

Mouse genital development depends on male or female hormones for specific features.

Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.

Human enzymes can detoxify harmful substances but might also increase their cancer risk.

Men are more likely to get infectious skin diseases, while women are more prone to autoimmune and pigment-related skin conditions, influenced by biological and environmental factors.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

Menopause significantly reduces skin collagen, leading to thinner, less elastic skin, and hormone replacement may help but requires careful consideration.

The effects of estrogen on human hair growth are unclear and need more research.

Androgens and estrogens are crucial for male reproductive health, affecting hormone levels and tissue function.

Trilostane treatment led to full hair regrowth in most Pomeranians and all miniature poodles with alopecia X.

Young women with diffuse hair loss may have low SHBG levels, which could lead to more active testosterone and contribute to their hair loss.